NCT05768165

Brief Summary

Cardiovascular performance and overall fitness can be improved by high-intensity aerobic activity, and these benefits may be achievable by persons with rheumatic diseases. The investigators hypothesize that a 12-week high-intensity interval exercise program will provide substantial improvements in cardiovascular function, inflammation and symptoms affecting quality of life.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P50-P75 for not_applicable rheumatoid-arthritis

Timeline
7mo left

Started Aug 2021

Longer than P75 for not_applicable rheumatoid-arthritis

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Aug 2021Dec 2026

Study Start

First participant enrolled

August 16, 2021

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

September 6, 2021

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

March 14, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Expected
Last Updated

December 22, 2025

Status Verified

December 1, 2025

Enrollment Period

1.9 years

First QC Date

September 6, 2021

Last Update Submit

December 15, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cardiopulmonary function

    Maximum oxygen uptake (VO2ml/min/kg) (Higher value indicate better cardiorespiratory capacity)

    0 -12 weeks

Secondary Outcomes (42)

  • Vascular function

    0-12 weeks

  • Level of disease activity

    0-12 weeks

  • Level of disease activity

    0-6 months

  • Level of disease activity

    0-12 months

  • Homeostatic model assessment of insulin resistance (HOMA IR)

    0-12 weeks

  • +37 more secondary outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Cardiorespiratory and strength exercise training 2-3 sessions per week

Behavioral: High intensity exercise

Care as usual

NO INTERVENTION

Care as usual and information of health enhancing physical activity according to general recommendations

Interventions

Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets. Exercise guidance follows principles of self-efficacy and person-centeredness.

Also known as: Person- centeredness
Intervention group

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Rheumatoid arthritis disease according to the American College of Rheumatology (ACR)/ The European Alliance of Associations for Rheumatology (EULAR) 1987/2010 criteria
  • Disease duration \>1 year
  • Age (range 20-60 years)
  • Stable medication on anti- rheumatic drugs for \>3 months
  • Low-to-moderate disease activity (\<5.1) according to the Disease activity score 28 (DAS28)

You may not qualify if:

  • Cerebrovascular diseases
  • Diabetes
  • Severe hypertension
  • Chronic obstructive pulmonary disease or other severe pulmonary diseases
  • Other severe diseases that may be associated with adverse events or restrict participation in high-intensity exercise
  • Arthroplasty of large joints
  • Inability to manage Cardiopulmonary Exercise Testing (CPET)
  • Pregnancy
  • Already participating in regular aerobic or strength exercise at a high intensity level (\>1 hours/ week) during the last 6 months
  • Inability to speak or read Swedish.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Sahlgrenska university hospital

Gothenburg, 413 45, Sweden

Location

Uddevalla Hospital

Uddevalla, Sweden

Location

Related Publications (2)

  • Bilberg A, Bjersing J, Borjesson M, Sivertsson J, Mannerkorpi K. High-intensity exercise improves multidimensional fatigue and health-related quality of life in rheumatoid arthritis: a randomized controlled study. Arthritis Res Ther. 2025 Sep 18;27(1):176. doi: 10.1186/s13075-025-03643-3.

  • Bilberg A, Mannerkorpi K, Borjesson M, Svedlund S, Sivertsson J, Klingberg E, Bjersing J. High-intensity interval training improves cardiovascular and physical health in patients with rheumatoid arthritis: a multicentre randomised controlled trial. Br J Sports Med. 2024 Dec 2;58(23):1409-1418. doi: 10.1136/bjsports-2024-108369.

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

High-Intensity Interval Training

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Physical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Annelie Bilberg, PhD

    Vastra Gotaland Region

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Single blinded
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Intervention versus care as usual
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2021

First Posted

March 14, 2023

Study Start

August 16, 2021

Primary Completion

June 30, 2023

Study Completion (Estimated)

December 30, 2026

Last Updated

December 22, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Individual participant data (IPD) that underlie results in a publication are available from the principal investigator (P.I.) on reasonable request. Access will be determined based on reasonable request and in accordance with the ethical approval

Time Frame
The data will become available as following, starting 6 months after publication and end 5 years after publication.
Access Criteria
The requests will be reviewed by the P.I. and the steering committee. Study plans on meta-analyses generating new knowledge on exercise in persons with rheumatic diseases will be approved.

Locations